A psilocybin-like drug targeting specific receptors in just the right amount could be an effective treatment for opiate addiction as well as eating disorders—two conditions that the COVID-19 pandemic and subsequent economic havoc and social-distancing isolation can trigger—and treatment-resistant epilepsy.